透明质酸声带注射填充术的安全性评估
本研究回顾性分析单中心299例使用Restylane-L的声带注射填充术,评估炎症反应、注射量与新冠疫苗接种状态的关系。总体并发症率为4.0%(12/299),炎症并发症占2.34%(7/299),炎症症状平均于注射后4.3天出现,全部经皮质类固醇治疗缓解。注射量组间差异有统计学意义(p=0.037),新冠疫苗接种状态与并发症率无关(p=0.84)。
要点
- 透明质酸声带注射填充术总体并发症率低,炎症反应经皮质类固醇治疗均可缓解。
- 炎症症状平均在注射后4.3天出现(中位3天,范围12小时至10天)。
- 注射量可能与并发症风险相关,但事后比较未达显著,需多中心研究验证。
核心结论
- 透明质酸声带注射填充术并发症率低,所有炎症反应经药物管理均缓解。
- 注射量可能影响并发症风险,但需进一步多中心研究证实。
- 未发现新冠疫苗接种状态与不良结局存在关联。
研究设计与样本
- 单中心回顾性队列研究,纳入299例使用Restylane-L的声带注射填充术。
- 通过病历回顾收集人口学、注射细节(入路、位置、体积)、喉频闪喉镜及注射后结局。
主要发现
- 总体并发症率为4.0%(12/299),炎症并发症占2.34%(7/299)。
- 炎症症状平均于注射后4.3天出现(中位3天,范围12小时至10天),全部经皮质类固醇治疗缓解。
- 注射量组间差异有统计学意义(p=0.037),但事后比较未达显著。
- 新冠疫苗接种状态与并发症率无关(p=0.84)。
临床怎么用
- 临床可参考本研究中透明质酸声带注射填充术的低并发症率及炎症反应的可管理性。
- 注射量可能影响并发症风险,操作时需关注注射体积的选择。
- 新冠疫苗接种状态不应作为禁忌或风险分层依据。
局限性
- 单中心回顾性设计可能限制结果外推。
- 注射量与并发症风险的关系需多中心研究进一步验证。
- 事后比较未显示显著性,注射量的作用需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study's objective is to assess the safety profile and complication rates of hyaluronic acid-based vocal fold injection augmentation (VFIA), specifically evaluating inflammatory reactions, injection volume, and COVID-19 vaccination status. METHODS: A retrospective cohort study was conducted of 299 VFIA procedures performed using Restylane-L at a single academic institution. Medical charts were reviewed to collect patient demographics, injection details (approach, location, and volume), videolaryngostroboscopy exams, and post-injection outcomes, including complication rates and nature of inflammatory reactions. RESULTS: The overall complication rate was 4.0% (12/299), with inflammatory complications comprising 2.34% (7/299) of cases. Inflammatory symptoms developed a mean of 4.3 days after injection (median: 3 days; range: 12 h-10 days) and resolved in all cases with corticosteroid therapy. A statistically significant difference in injection volume was noted among groups (p = 0.037), although post hoc comparisons did not demonstrate significance. COVID-19 vaccination status was not associated with complication rates (p = 0.84). CONCLUSIONS: VFIA using HA-based material demonstrates a low rate of complications, and all inflammatory reactions resolved with medical management. Injection volume may play a role in complication risk, but further multi-site studies are needed. No association between COVID-19 vaccination and adverse outcomes was identified.
引用
- Thornton N, Stepp R, Nguyenkhoa V, et al. Safety Profile in Hyaluronic Acid-Based Vocal Fold Injection Augmentation. Laryngoscope. 2026. PMID: 41873110. doi:10.1002/lary.70513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。